Stock NKTR NEKTAR THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nektar Therapeutics

Equities

NKTR

US6402681083

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.32 USD 0.00% Intraday chart for Nektar Therapeutics +6.45% +133.63%
Apr. 24 Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases CI
Mar. 19 Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,797 3,050 2,493 424.8 107.8 242.4 - -
Enterprise Value (EV) 1 3,951 1,988 1,759 -80.2 72.51 127.6 -39.04 242.4
P/E ratio -8.57 x -6.83 x -4.72 x -1.15 x -0.39 x -1.56 x -1.97 x -2.01 x
Yield - - - - - - - -
Capitalization / Revenue 33.1 x 19.9 x 24.5 x 4.61 x 1.2 x 3.34 x 3.55 x 3.81 x
EV / Revenue 34.5 x 13 x 17.3 x -0.87 x 0.8 x 1.76 x -0.57 x 3.81 x
EV / EBITDA -9.25 x -4.84 x -4.07 x 0.22 x -0.28 x -1.04 x 0.3 x -1.51 x
EV / FCF -11.1 x -6.2 x -4.11 x 0.26 x -0.37 x -0.87 x 0.21 x -1.38 x
FCF Yield -8.99% -16.1% -24.3% 386% -267% -115% 469% -72.6%
Price to Book 2.71 x 2.84 x 3.69 x 1.16 x 0.83 x 7.57 x 2.7 x -
Nbr of stocks (in thousands) 175,922 179,399 184,557 187,954 190,771 183,618 - -
Reference price 2 21.58 17.00 13.51 2.260 0.5650 1.320 1.320 1.320
Announcement Date 2/27/20 2/25/21 2/28/22 2/28/23 3/4/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 114.6 152.9 101.9 92.06 90.12 72.54 68.35 63.57
EBITDA 1 -426.9 -410.9 -432.3 -363.1 -255.9 -122.2 -130.6 -160.3
EBIT 1 -440 -425.1 -446.4 -376.2 -263.7 -161.4 -157.5 -174.6
Operating Margin -383.92% -278% -438.05% -408.63% -292.59% -222.45% -230.5% -274.6%
Earnings before Tax (EBT) 1 -440.1 -443.9 -523.3 -365 -276.3 -167.7 -167.3 -180.6
Net income 1 -440.7 -444.4 -523.8 -368.2 -276.1 -167.9 -167.5 -180.8
Net margin -384.47% -290.65% -514.03% -399.98% -306.31% -231.43% -245.01% -284.44%
EPS 2 -2.520 -2.490 -2.860 -1.970 -1.450 -0.8487 -0.6694 -0.6575
Free Cash Flow 1 -355 -320.5 -427.6 -309.7 -193.5 -147 -183 -176
FCF margin -309.7% -209.62% -419.65% -336.41% -214.67% -202.65% -267.75% -276.87%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/28/22 2/28/23 3/4/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 24.92 25.01 24.82 21.58 23.62 22.02 21.59 20.5 24.14 23.88 15.34 15.34 15.34 15.34
EBITDA -110 -109.5 -112.8 -149.4 -51.62 -49.29 -42.71 - - -31.86 - - - -
EBIT 1 -113.6 -112.9 -116.6 -152.8 -54.3 -52.47 -45.01 -50.6 -44.86 -33.51 -38.93 -38.85 -39.07 -40.81
Operating Margin -455.82% -451.48% -469.58% -708.07% -229.85% -238.25% -208.44% -246.84% -185.82% -140.3% -253.73% -253.25% -254.68% -266.03%
Earnings before Tax (EBT) 1 -129.6 -145.6 -90.27 -159 -59.2 -56.54 -137.1 -51.17 -45.9 -42.11 -40.1 -41.85 -43.6 -44.9
Net income 1 -129.7 -145.6 -90.39 -159.1 -59.05 -59.69 -137 -51.12 -45.84 -42.08 -40.1 -41.85 -43.6 -44.9
Net margin -520.47% -582.37% -364.16% -736.94% -249.94% -271.03% -634.52% -249.39% -189.85% -176.17% -261.38% -272.79% -284.19% -292.67%
EPS 2 -0.7000 -0.7900 -0.4900 -0.8500 -0.3100 -0.3200 -0.7300 -0.2700 -0.2400 -0.2200 -0.1967 -0.1967 -0.1967 -0.2033
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/28/22 5/5/22 8/4/22 11/3/22 2/28/23 5/9/23 8/8/23 11/7/23 3/4/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 153 - - - - - - -
Net Cash position 1 - 1,062 734 505 35.3 115 281 -
Leverage (Debt/EBITDA) -0.359 x - - - - - - -
Free Cash Flow 1 -355 -321 -428 -310 -193 -147 -183 -176
ROE (net income / shareholders' equity) -28.2% -35.8% -59.6% -70.4% -111% -159% -165% -
ROA (Net income/ Total Assets) -21.4% -25.3% -39.4% -40.3% -49.8% -36.8% -39.4% -
Assets 1 2,064 1,758 1,328 913.9 554.3 456.8 425.4 -
Book Value Per Share 2 7.960 5.980 3.660 1.940 0.6800 0.1700 0.4900 -
Cash Flow per Share - - -2.250 -1.620 - - - -
Capex 1 26.3 7.26 15 5.68 0.86 13 - -
Capex / Sales 22.93% 4.75% 14.71% 6.17% 0.95% 17.92% - -
Announcement Date 2/27/20 2/25/21 2/28/22 2/28/23 3/4/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Nektar Therapeutics

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.32 USD
Average target price
1 USD
Spread / Average Target
-24.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NEKTAR THERAPEUTICS Stock Nektar Therapeutics
+133.63% 242M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NKTR Stock
  4. Financials Nektar Therapeutics